U.S. FDA Approves FoundationOneLiquid CDx as a Companion Diagnostic for Pfizer's BRAFTOVI (encorafenib) in Combination with Cetuximab to Identify Patients with BRAF V600E Alterations in Metastatic Colorectal Cancer
In: Wireless News, 2023-06-30
Zeitungsartikel
Zugriff:
Titel: |
U.S. FDA Approves FoundationOneLiquid CDx as a Companion Diagnostic for Pfizer's BRAFTOVI (encorafenib) in Combination with Cetuximab to Identify Patients with BRAF V600E Alterations in Metastatic Colorectal Cancer
|
---|---|
Zeitschrift: | Wireless News, 2023-06-30 |
Veröffentlichung: | 2023 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|